














## The new diagnostic tool for management of rhinitis or asthma patients

Are the respiratory symptoms allergic or non-allergic? You need to know!

- New FDA-cleared, point-of-care testing device
- Knowing the patient's inhalant specific IgE profile guides individualized management of symptoms



Each ImmunoCAP® Rapid assay device measures specific IgE for the following seasonal and perennial inhalant allergens:

|   |   |   |   |
|---|---|---|---|
|  | e1 Cat  |  | m6 Mold ( <i>A alternata</i> )          |
|  | d1 House dust mite ( <i>D pteronyssinus</i> ) |  | g6 Timothy grass                        |
|  | g2 Bermuda grass                              |  | t8 Elm                                  |
|  | w1 Common ragweed                             |  | e5 Dog                                  |
|  | t7 Oak  |  | d2 House dust mite ( <i>D farinae</i> ) |

### ImmunoCAP Rapid features

- Provides 10 semi-quantitative specific IgE results in 20 minutes
- Ideal for use in physician office laboratories with a moderate complexity license
- Minimal training required
- Small footprint
- Single blood draw

***“Demonstrating a patient’s relevant sensitivity to inhalant allergens will enable the clinician to recommend specific environmental controls to reduce exposures.”<sup>1</sup>***

—National Institutes of Health

# The value of ImmunoCAP® Rapid results

## Technical performance

Overall agreement with ImmunoCAP Specific IgE (sIgE) blood test = 92%<sup>2</sup>


- ImmunoCAP Rapid Class 1 results indicate the low probability of the presence of allergy
  - 94% agreement between ImmunoCAP Rapid results and ImmunoCAP sIgE blood test results<sup>2</sup>
- ImmunoCAP Rapid Class 2 and 3 results indicate moderate to high probability of the presence of allergy
  - 89% agreement between ImmunoCAP Rapid results and ImmunoCAP sIgE blood test results<sup>2</sup>

## Clinical utility

When used in conjunction with history and physical exam, ImmunoCAP Rapid results offer objective evidence to help

- Rule in/rule out atopy as the cause of allergic symptoms<sup>1,3</sup>
- Identify specific allergic triggers<sup>1,3</sup>
- Select appropriate targeted treatments<sup>4</sup>
- Implement targeted exposure reduction to specific allergens<sup>1,3</sup>

## Respiratory allergy: a cumulative threshold disease



Most patients are sensitive to more than one thing.<sup>5</sup> For these patients, symptoms appear only when they are exposed to two or more allergic triggers at once.<sup>6</sup>

## Reimbursement information

| Common Procedural Terminology (CPT) code applicable to ImmunoCAP Rapid testing<br>CPT code 86003 x 10 (the number of included allergens) |   |                                    |
|--|---|------------------------------------|
| CPT Code   | Explanation   | Description/Comments               |
| 86003  | Allergen-Specific IgE, Quantitative or Semi-Quantitative, Each Allergen | Indicate Number of Tests Performed |

### References:

1. NIH. *Guidelines for the Diagnosis and Management of Asthma, 2007*. NIH publication 08-4051.
2. Directions for Use. ImmunoCAP® Rapid Inhalant Profile 1. Phadia AB.
3. Wallace DV, et al. *J Allergy Clin Immunol*. 2008;122(2 suppl):S1-S84.
4. Roberts RG. *Patient Care*. 2004;38(6):28-33.
5. Arbes SJ, et al. *J Allergy Clin Immunol*. 2005;116(2):377-383.
6. Wickman M. *Allergy*. 2005;60 (suppl 79):14-18.

[www.immunocaprapid.com](http://www.immunocaprapid.com)

ImmunoCAP is a US registered trademark of Phadia AB  
©2010 Phadia US Inc., a subsidiary of Phadia AB

**Phadia**  
Setting the Standard

Phadia US Inc  
4169 Commercial Avenue  
Portage, MI 49002  
800.346.4364

482435.01